PROTACs Explained: Chemistry of Targeted Protein Degraders

Added:

Molecular Glues and the Pharmacokinetic Limitations of PROTACs

While PROTACs offer a revolutionary approach to targeted protein degradation, they face significant hurdles due to their high molecular weight and chemical complexity. Because PROTACs are large, bifunctional molecules, they frequently violate Lipinski’s 'Rule of Five,' leading to poor oral bioavailability, limited tissue penetration, and complex formulation challenges. They also suffer from the 'hook effect,' where high drug concentrations counterproductively prevent the formation of the active ternary complex. In response, many researchers champion 'molecular glues' as a superior alternative paradigm. Molecular glues are smaller, monovalent molecules that induce proximity between an E3 ligase and a target protein by modifying the ligase's surface. Due to their compact size, molecular glues typically exhibit far better drug-like properties, superior pharmacokinetics, and simpler synthesis, presenting a major competing approach in targeted protein degradation.

The Ubiquitin-Proteasome System (UPS): Understanding how cells naturally target and degrade proteins using ubiquitin tags and the 26S proteasome.
Medicinal Chemistry Principles: Familiarity with ligand-receptor interactions, binding affinity, selectivity, and structure-activity relationships (SAR).
Protein Structure and Kinase Biology: Knowledge of how kinases function in cell signaling and how inhibitors traditionally target their active sites.
Ternary Complex Biophysics: Exploring the thermodynamics, cooperativity, and structural kinetics of the E3 ligase-PROTAC-target protein complex.
Beyond Rule-of-Five (bRo5) Pharmacokinetics: Investigating the absorption, distribution, metabolism, and excretion (ADME) challenges unique to large chimeric molecules.
Alternative Targeted Protein Degradation (TPD) Modalities: Studying molecular glues, LYTACs (Lysosome-targeting chimeras), and AUTACs (Autophagy-targeting chimeras).
Clinical Resistance Mechanisms: Analyzing how tumor cells develop resistance to PROTACs through E3 ligase mutations or genomic alterations.
2K views27likes40:01@LabrootsOriginal Release: 2021-03-16

PROTACs (Proteolysis Targeting Chimeras) are bifunctional molecules consisting of a target protein ligand, a linker, and an E3 ubiquitin ligase ligand that act as molecular glues to bring target proteins into proximity with E3 ligases, enabling ubiquitin-mediated degradation through the proteasome; this technology has revolutionized drug discovery by enabling targeting of previously undruggable proteins, with successful applications in nuclear hormone receptors (SERDs, SARDs), kinases, and other oncology targets, though challenges remain in optimizing biophysical properties and achieving predictable outcomes.